Stopping the cardiovascular disease continuum: Focus on prevention.

The cardiovascular disease continuum (CVDC) is a sequence of events, which begins from a host of cardiovascular risk factors that consists of diabetes mellitus, dyslipidemia, hypertension, smoking and visceral obesity. If it is not intervened with early, it inexorably progresses to atherosclerosis, coronary artery disease, myocardial infarction, left ventricular hypertrophy, and left ventricular dilatation, which lead to left ventricular diastolic or systolic dysfunction and eventually end-stage heart failure and death. Treatment intervention at any stage during its course will either arrest or delay its progress. In this editorial, the cardiovascular risk factors that initiate and perpetuate the CVDC are briefly discussed, with an emphasis on their early prevention or aggressive treatment.

• Publication year

  2010

• Venue

  World Journal of Cardiology

• Publication date

  2010-03-26

• Fields of study

  Medicine

• Identifiers
  DOI 10.4330/wjc.v2.i3.43PMID 21160754PMCID PMC2999025
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The J-Curve Between Blood Pressure and Coronary Artery Disease or Essential Hypertension: Exactly How Essential?

  2010cited by this paper
• Impact of Abdominal Obesity on Incidence of Adverse Metabolic Effects Associated With Antihypertensive Medications

  2010cited by this paper
• Prevalence and trends in obesity among US adults, 1999-2008.

  2010cited by this paper
• The J-curve between blood pressure and coronary artery disease or essential hypertension: exactly how essential?

  2009cited by this paper
• Effects of Intensive Glucose Lowering in Type 2 Diabetes

  2009cited by this paper
• Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study

  2009cited by this paper
• Smoking status and long-term survival after first acute myocardial infarction a population-based cohort study.

  2009cited by this paper
• A comprehensive review on salt and health and current experience of worldwide salt reduction programmes

  2009cited by this paper
• The association of pediatric low- and high-density lipoprotein cholesterol dyslipidemia classifications and change in dyslipidemia status with carotid intima-media thickness in adulthood evidence from the cardiovascular risk in Young Finns study, the Bogalusa Heart study, and the CDAH (Childhood Det

  2009cited by this paper
• Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction

  2009cited by this paper
• Diabetes in Asia: epidemiology, risk factors, and pathophysiology.

  2009cited by this paper
• Beyond low-density lipoprotein cholesterol: respective contributions of non-high-density lipoprotein cholesterol levels, triglycerides, and the total cholesterol/high-density lipoprotein cholesterol ratio to coronary heart disease risk in apparently healthy men and women.

  2009cited by this paper
• Effect of the Direct Renin Inhibitor Aliskiren, the Angiotensin Receptor Blocker Losartan, or Both on Left Ventricular Mass in Patients With Hypertension and Left Ventricular Hypertrophy

  2009cited by this paper
• Glucose control and vascular complications in veterans with type 2 diabetes.

  2009cited by this paper
• The Metabolic Syndrome in South Asians: Epidemiology, Determinants, and Prevention

  2009cited by this paper
• Total cardiovascular disease burden: comparing intensive with moderate statin therapy insights from the IDEAL (Incremental Decrease in End Points Through Aggressive Lipid Lowering) trial.

  2009cited by this paper
• Treating Tobacco Use and Dependence: 2008 Update U.S. Public Health Service Clinical Practice Guideline Executive Summary

  2008cited by this paper
• The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure – a prospective, randomized, controlled prevention trial of the German Hypertension League

  2008cited by this paper
• A clinical practice guideline for treating tobacco use and dependence: 2008 update. A U.S. Public Health Service report.

  2008cited by this paper
• Angiotensin II receptor blockers in the treatment of the cardiovascular disease continuum.

  2008cited by this paper
• Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials

  2008cited by this paper
• Development of heart failure in recent hypertension trials

  2008cited by this paper
• Depression: a predictor of smoking relapse in a 6-month follow-up after hospitalization for acute coronary syndrome

  2008cited by this paper
• The early life origins of vascular ageing and cardiovascular risk: the EVA syndrome

  2008cited by this paper
• Heart failure with preserved ejection fraction: treat now by treating comorbidities.

  2008cited by this paper
• Standards of Medical Care in Diabetes—2008 The recommendations in this article are based on the evidence reviewed in the following publication: Standards of care for diabetes (Technical Review). Diabetes Care 17:1514–1522, 1994. Originally approved 1988. Most recent review/revision, October 2007.

  2008cited by this paper
• Heart disease and stroke statistics--2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee.

  2008cited by this paper
• Standards of Medical Care in Diabetes—2008

  2008cited by this paper
• Effects of intensive glucose lowering in type 2 diabetes.

  2008cited by this paper
• Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.

  2008cited by this paper
• Obesity, Metabolic Syndrome, and Cardiovascular Disease

  2007cited by this paper
• Heart disease and stroke statistics--2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee.

  2007cited by this paper
• Blood pressure-dependent and independent effects of agents that inhibit the renin–angiotensin system

  2007cited by this paper
• Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis.

  2007cited by this paper
• Mellitus: A Scientific Statement From the American Heart Association and the Primary Prevention of Cardiovascular Diseases in People With Diabetes

  2007cited by this paper
• Prediction of Clinical Cardiovascular Events With Carotid Intima-Media Thickness: A Systematic Review and Meta-Analysis

  2007cited by this paper
• An Update on the Etiology and Epidemiology of Diabetes Mellitus

  2006cited by this paper
• Obesity and Cardiovascular Disease: Pathophysiology, Evaluation, and Effect of Weight Loss: An Update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease From the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism

  2006cited by this paper
• Significance of small dense low-density lipoprotein-cholesterol concentrations in relation to the severity of coronary heart diseases.

  2006cited by this paper
• Feasibility of treating prehypertension with an angiotensin-receptor blocker.

  2006cited by this paper
• The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease).

  2006cited by this paper
• Blood Pressure Reduction and Cardiovascular Prevention: An Update Including the 2003–2004 Secondary Prevention Trials

  2005cited by this paper
• Intensive lipid lowering with atorvastatin in patients with stable coronary disease.

  2005cited by this paper
• Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males.

  2005cited by this paper
• Obesity, metabolic syndrome, and cardiovascular disease.

  2004cited by this paper
• Preventing cancer, cardiovascular disease, and diabetes: a common agenda for the American Cancer Society, the American Diabetes Association, and the American Heart Association.

  2004cited by this paper
• Mortality in relation to smoking: 50 years' observations on male British doctors

  2004cited by this paper
• The pathophysiology of cigarette smoking and cardiovascular disease: an update.

  2004cited by this paper
• Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.

  2004cited by this paper
• Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines

  2004cited by this paper
• Preventing Cancer, Cardiovascular Disease, and Diabetes: A Common Agenda for the American Cancer Society, the American Diabetes Association, and the American Heart Association

  2004cited by this paper
• Long-Term Effects of Irbesartan and Atenolol on the Renin-Angiotensin-Aldosterone System in Human Primary Hypertension: The Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA)

  2003cited by this paper
• Systolic Blood Pressure, Diastolic Blood Pressure, and Pulse Pressure as Predictors of Risk for Congestive Heart Failure in the Framingham Heart Study

  2003cited by this paper
• Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review.

  2003cited by this paper
• Abdominal Obesity and Risk of Ischemic Stroke: The Northern Manhattan Stroke Study

  2003cited by this paper
• Increase in blood glucose concentration during antihypertensive treatment as a predictor of myocardial infarction: population based cohort study

  2003cited by this paper
• Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

  2003cited by this paper
• Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

  2002cited by this paper
• Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies.

  2002cited by this paper
• Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study

  2002cited by this paper
• Prevalence and trends in obesity among US adults, 1999-2000.

  2002cited by this paper
• Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial.

  2002cited by this paper
• Effect of smoking cessation on mortality after myocardial infarction: meta-analysis of cohort studies.

  2000cited by this paper
• MORTALITY FROM CORONARY HEART DISEASE IN SUBJECTS WITH TYPE 2 DIABETES AND IN NONDIABETIC SUBJECTS WITH AND WITHOUT PRIOR MYOCARDIAL INFARCTION

  2000cited by this paper
• Diabetes mellitus: perspective from the Asia-Pacific region.

  2000cited by this paper
• Impact of smoking cessation and smoking interventions in patients with coronary heart disease.

  1999cited by this paper
• Assessment of Cardiovascular Risk by Use of Multiple-Risk-Factor Assessment Equations

  1999cited by this paper
• Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology.

  1999cited by this paper
• Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction.

  1998cited by this paper
• Vascular remodeling: the role of angiotensin-converting enzyme inhibitors.

  1998cited by this paper
• Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension.

  1998cited by this paper
• No excess 12-year mortality in men with impaired glucose tolerance who participated in the Malmö Preventive Trial with diet and exercise

  1998cited by this paper
• Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials.

  1996cited by this paper
• Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the Treatment of Mild Hypertension Study (TOMHS).

  1995cited by this paper
• Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement.

  1991cited by this paper
• A general cardiovascular risk profile: the Framingham Study.

  1976cited by this paper
• Smoking and myocardial infarction.

  1975cited by this paper
• Smoking and Myocardial Infarction

  1969cited by this paper
• For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group

  year unknowncited by this paper
• Circulation Editors’ Picks Most Read Articles in Hypertension the Angiotensin Receptor Blocker Losartan, or Both on Left Ventricular Mass in Patients With Hypertension and Left Ventricular Hypertrophy

  year unknowncited by this paper

• Mitochondrial Dysfunction and Atherosclerosis: The Problem and the Search for Its Solution

  2025cites this paper
• Mitochondrial Dysfunction and Risk Factors for Noncommunicable Diseases: From Basic Concepts to Future Prospective

  2024cites this paper
• Spatial and temporal trends of overweight/obesity and tobacco use in East Africa: subnational insights into cardiovascular disease risk factors

  2023cites this paper
• Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes

  2022cites this paper
• Glucocorticoid toxicity reduction with mepolizumab using the Glucocorticoid Toxicity Index

  2021cites this paper
• The influence of Cytoflavin on molecular mechanisms of myocardial and vascular wall remodeling in patients with sistolic arterial hypertension

  2018cites this paper
• Changes in pulmonary artery systolic pressure correlate with radiographic severity and peripheral oxygenation in adults with community‐acquired pneumonia

  2018cites this paper
• Prognostičko značenje hipertrofije lijeve klijetke u kardiovaskularnom kontinuumu

  2017cites this paper
• Exogenous cathepsin V protein protects human cardiomyocytes HCM from angiotensin Ⅱ-Induced hypertrophy.

  2017cites this paper
• Hypertension and Sexual Health

  2017cites this paper
• Characteristics of NRS-2002 Nutritional Risk Screening in Patients Hospitalized for Secondary Cardiovascular Prevention and Rehabilitation

  2014cites this paper
• Cathepsin S as a biomarker of low-grade inflammation, insulin resistance, and cardiometabolic disease risk

  2014cites this paper
• Uptodate on GH/IGF-1 axis actions

  2013cites this paper
• Effectiveness of the fixed-dose combination of olmesartan/amlodipine/hydrochlorothiazide for the treatment of hypertension in patients stratified by age, race and diabetes, CKD and chronic CVD

  2013cites this paper
• Clinical Lipid Control Success Rate Before and After Percutaneous Coronary Intervention in Iran; a Single Center Study

  2013influential citation
• Usefulness of pet ownership as a modulator of cardiac autonomic imbalance in patients with diabetes mellitus, hypertension, and/or hyperlipidemia.

  2012cites this paper
• Position of cardiovascular rehabilitation programs in the global burden of cardiovascular diseases

  2012cites this paper
• Suvremeni programi kardiološke rehabilitacije u globalnom bremenu kardiovaskularnih bolesti

  2012cites this paper
• Triple-drug, fixed-dose combinations for the treatment of hypertension: focus on olmesartan/amlodipine/hydrochlorothiazide combination.

  2011cites this paper
• Characterization ofAthsq1, an Atherosclerosis Modifier Locus on Mouse Chromosome 4:

  2011influential citation
• Association between serum cathepsin S and mortality in older adults.

  2011cites this paper
• [Cardiovascular continuum: possibilities of coenzyme-q in correction of oxidative stress].

  2011cites this paper
• World Journal of Cardiology

  year unknowncites this paper